KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.60

Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.

Tomonori Habuchi

Eur Urol 84(1) 141-142

PMID36870797
PMCID-
DOI10.1016/j.eururo.2023.02.021
发表日期2023-03-04
入排依据:The record is an eligible-type report (Phase 3b, randomized, oncology, human, drug intervention, original result). However, the abstract is missing, and the title does not explicitly state a time-to-event efficacy endpoint (e.g., OS, PFS) or mention Kaplan-Meier/HR. Metadata cannot confirm the 'time_to_event' criterion without this information. Therefore, is_eligible is set to null.
摘要

摘要

无摘要

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。